FDA approves MabThera for leukaemia

Friday 19 February 2010

The US Food and Drug Administration has approved MabThera ( rituximab), plus chemotherapy, for people with previously untreated or previously treated CD20-positive chronic lymphocytic leukaemia, the Roche group announced.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland